Buscar
21/05/2025
TRIPLE THERAPY WITH BELIMUMAB IN PROLIFERATIVE LUPUS NEPHRITIS: REAL-WORLD EFFICACY AND GLUCOCORTICOID-SPARING EFFECTS
Vidal-Montal, P, Fabregat, A, Heredia, S, Bernardez, J, Magallares, BP, Gómez-Puerta, J, Frade-Sosa, B, Nolla, JM, Narváez, J. TRIPLE THERAPY WITH BELIMUMAB IN PROLIFERATIVE LUPUS NEPHRITIS: REAL-WORLD EFFICACY AND GLUCOCORTICOID-SPARING EFFECTS. JOURNAL OF RHEUMATOLOGY. 2025; 52DOI:. PMID:. IF:3.400(Q2/3D).
20/05/2025
In Vitro Immune Response of Mononuclear Cells to Multidrug-Resistant Escherichia coli
Cuyàs, B, Cantó, E, Sanchez-Ardid, E, Miró, E, Alvarado-Tapias, E, Román, E, Poca, M, Navarro, F, Ferrero-Gregori, A, Escorsell, MA, Vidal, S, Soriano, G. In Vitro Immune Response of Mononuclear Cells to Multidrug-Resistant Escherichia coli. Microorganisms. 2025; 13(5)DOI:10.3390/microorganisms13051164. PMID:40431335. IF:4.200(Q2/3D).
15/05/2025
25-year follow-up on marked ventricular repolarization abnormalities in athletes: Long-term outcomes and cardiovascular prognosis
Salido, M, Moliner-Abós, C, Zoratti, L, Puig, T, Carreras-Costa, F, Serra-Grima, R. 25-year follow-up on marked ventricular repolarization abnormalities in athletes: Long-term outcomes and cardiovascular prognosis. INTERNATIONAL JOURNAL OF CARDIOLOGY. 2025; 427DOI:10.1016/j.ijcard.2025.133060. PMID:40010514. IF:3.200(Q2/3D).
15/05/2025
Frameworks to support evidence-informed decision-making in public health and infectious disease prevention and control: a scoping review
Song, Y, Bracchiglione, J, Meneses-Echávez, J, Gomes, HD, Albiger, B, Solà, I, Rigau, D, Alonso-Coello, P. Frameworks to support evidence-informed decision-making in public health and infectious disease prevention and control: a scoping review. Eurosurveillance. 2025; 30(19)DOI:10.2807/1560-7917.ES.2025.30.19.2400185. PMID:40376818. IF:7.800(Q1/1D).
15/05/2025
Users' experience of frameworks to support evidence-informed decision-making in public health: a scoping review
Bracchiglione, J, Song, Y, Meneses-Echávez, JF, Gomes, HD, Albiger, B, Solà, I, Rigau, D, Alonso-Coello, P. Users' experience of frameworks to support evidence-informed decision-making in public health: a scoping review. Eurosurveillance. 2025; 30(19)DOI:10.2807/1560-7917.ES.2025.30.19.2400184. PMID:40376821. IF:7.800(Q1/1D).
15/05/2025
One-Year Recurrent Tricuspid Regurgitation After Successful Transcatheter Edge to Edge Repair: The TRI-SPA Registry
Echarte-Morales, J, Cepas-Guillén, P, Arzamendi, D, Moñivas, V, Carrasco-Chinchilla, F, Pan, M, Nombela-Franco, L, Pascual, I, Benito-González, T, Pérez, R, Gómez-Blázquez, I, Amat-Santos, IJ, Cruz-González, I, Sánchez-Recalde, A, Caneiro-Queija, B, Alvarez, ABC, Barreiro-Pérez, M, Sanchis, L, Li, CH, del Trigo, M, Martínez-carmona, JD, Mesa, D, Jiménez, P, Avanzas, P, Freixa, X, Estévez-Loureiro, R. One-Year Recurrent Tricuspid Regurgitation After Successful Transcatheter Edge to Edge Repair: The TRI-SPA Registry. AMERICAN JOURNAL OF CARDIOLOGY. 2025; 243DOI:10.1016/j.amjcard.2025.02.010. PMID:39984153. IF:2.100(Q3/6D).
15/05/2025
A deep attention-based encoder for the prediction of type 2 diabetes longitudinal outcomes from routinely collected health care data
Manzini, E, Vlacho, B, Franch-Nadal, J, Escudero, J, Génova, A, Reixach, E, Andrés, E, Pizarro, I, Mauricio, D, Perera-Lluna, A. A deep attention-based encoder for the prediction of type 2 diabetes longitudinal outcomes from routinely collected health care data. EXPERT SYSTEMS WITH APPLICATIONS. 2025; 274DOI:10.1016/j.eswa.2025.126876. PMID:. IF:7.500(Q1/1D).
14/05/2025
Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia: validation of the ELN-2021 MRD recommendations
Jimenez-Vicente, C, Cardus, A, Castaño-Diez, S, Ramil, G, Garcia-Avila, S, Gomez-Perez, L, Esteban, D, Arribas, I, Sturla, AL, Lopez-Guerra, M, Martinez-Roca, A, Cortes-Bullich, A, Perez-Valencia, AI, Zugasti, I, Monge, I, Carcelero, E, Vall-Llovera, F, Vives, S, Sierra, J, Nomdedeu, J, Oñate, G, Garrido, A, Pratcorona, M, Pomares, H, Arnan, M, Guijarro, F, Diaz-Beya, M, Esteve, J. Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia: validation of the ELN-2021 MRD recommendations. Blood Cancer Journal. 2025; 15(1)DOI:10.1038/s41408-025-01298-6. PMID:40368916. IF:11.600(Q1/1D).